Table 3.
Post-treatment clinical efficacy rate (FAS/PPS), rate difference (FAS/PPS), and inter-group comparison.
| Clinical efficacy | FAS | PPS | ||
|---|---|---|---|---|
| JHQG group | Placebo group | JHQG group | Placebo group | |
| Post-treatment clinical efficacy rate (FAS/PPS) | ||||
| No (ineffective, worsened) | 26 (17.33) | 133 (89.26) | 6 (4.65) | 111 (87.40) |
| Yes (clinically cured, remarkable effective and effective) | 124 (82.67) | 16 (10.74) | 123 (95.35) | 16 (12.60) |
| Rate difference | Test method | FAS | PPS | |
| Statistics | Statistics | |||
| Clinical efficacy rate difference (FAS/PPS) | ||||
| JHQG group-Placebo group | Rate difference (95% CI) | 71.93 (64.09, 79.76) | 82.75 (75.93, 89.57) | |
| Clinical efficacy rate | Model | FAS | PPS | |
| P -value | P -value | |||
| Inter-group comparison (FAS/PPS) | ||||
| JHQG group vs. Placebo group | Chi-square test | <0.0001 | <0.0001 | |